Deutsche Bank Upgrades Sepracor to 'Buy'
Sepracor (SEPR ) says it received an "approvable" letter from the FDA for its New Drug Application for Estorra brand eszopiclone. Deutsche Bank upgraded the stock to buy from hold.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.